Eotaxin and Oncostatin M (Fig.9) Our study establish these two chemokines as novel targets for devising novel anticancer therapy whereby targeting them using specific antibody may not only retard tumor progression on its own, but when administered in combination it may augment the efficacy of anti-angiogenic therapy, particularly in tumor that are refractory or develop resistance to anti-angiogenesis therapeutics. This evidence concerns the gene CCL11 and neoplasm.